LONDON and PHOENIX, Ariz., June 06, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today announced the establishment of a joint clinical collaboration agreement with University Hospitals.
Per the terms of this agreement, University Hospitals will provide tissue samples with clinical outcomes to AccuStem for research purposes. The scope of the agreement covers a multitude of different cancers but will initially focus on breast cancer cases to support further validation of the StemPrintER test. The goal of the initial project is to build on the strong foundation of data for StemPrintER by demonstrating additional clinical utility beyond identifying patients' risk of recurrence. This next step is critical for women with early stage breast cancer because there are many tests to determine the need for chemotherapy but there are no genomic tools to inform decisions earlier in the continuum of care. StemPrintER may be able to shift this paradigm by informing physicians of the most effective approaches to surgical or radiological treatment.
"AccuStem has arrived at an important juncture as we progress toward commercializing StemPrintER," said Wendy Blosser, Chief Executive Officer of AccuStem. "With this collaboration, we intend to expand beyond identifying a patient's prognosis by addressing unanswered clinical questions and supporting surgeons and radiation oncologists with their treatment planning."
AccuStem and its clinical collaborators plan to present the data obtained under this agreement at scientific conferences and to publish the findings in peer-reviewed medical journals. Those activities will help to bolster the foundation of data for StemPrintER and familiarize physicians with its utility and value in clinical decision making with the ultimate goal of improving patient outcomes and quality of life.
"We are excited to work with AccuStem on this clinical project," said Hannah Gilmore, Division Chief, Anatomic Pathology, University Hospitals Cleveland Medical Center and Professor of Pathology, Case Western Reserve University. "I am very interested in the foundation for the StemPrintER test and think that it could have important implications for treatment planning in breast cancer and perhaps many other tumor types."
About AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor "stemness", we believe our tools will help care teams better understand the biology of each patient's cancer, leading to more informed decision making. For more information, please visit .
About University Hospitals / Cleveland, Ohio
Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 21 hospitals (including five joint ventures), more than 50 health centers and outpatient facilities, and over 200 physician offices in 16 counties throughout northern Ohio. The system's flagship quaternary care, academic medical center, University Hospitals Cleveland Medical Center, is affiliated with Case Western Reserve University School of Medicine, Northeast Ohio Medical University, Oxford University, the Technion Israel Institute of Technology and Taiwan University College of Medicine. The main campus also includes the UH Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, with more than 3,000 active clinical trials and research studies underway. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including "America's Best Hospitals" from U.S. News & World Report. UH is also home to 19 Clinical Care Delivery and Research Institutes. UH is one of the largest employers in Northeast Ohio with more than 30,000 employees.
倫敦和亞利桑那州菲尼克斯,2023年6月6日(GLOBE NEWSWIRE)——致力於改善癌症患者預後的臨床階段診斷公司AccuStem Sciences, Inc.(OTCQB:ACUT)今天宣佈與大學醫院簽訂聯合臨床合作協議。
根據該協議的條款,大學醫院將向AccuStem提供具有臨床結果的組織樣本,用於研究目的。該協議的範圍涵蓋多種不同的癌症,但最初將側重於乳腺癌病例,以支持StemPrinter測試的進一步驗證。最初項目的目標是在StemPrinter的堅實數據基礎上再接再厲,展示除識別患者復發風險之外的其他臨床用途。下一步對於患有早期乳腺癌的女性至關重要,因爲有許多測試可以確定化療的必要性,但是沒有基因組工具可以在護理的早期階段爲決策提供信息。StemPrinter 可以通過告知醫生最有效的外科或放射治療方法來改變這種模式。
AccuStem首席執行官溫迪·布洛瑟說:“隨着我們在StemPrinter商業化方面取得進展,AccuStem已經到了一個重要時刻。”“通過此次合作,我們打算通過解決懸而未決的臨床問題以及支持外科醫生和放射腫瘤學家制定治療計劃,將範圍擴大到確定患者的預後之外。”
AccuStem及其臨床合作者計劃在科學會議上介紹根據該協議獲得的數據,並在同行評審的醫學期刊上發表研究結果。這些活動將有助於鞏固StemPrinter的數據基礎,並使醫生熟悉其在臨床決策中的效用和價值,最終目標是改善患者的預後和生活質量。
克利夫蘭大學醫院醫學中心解剖病理學系主任、凱斯西儲大學病理學教授漢娜·吉爾摩說:“我們很高興能與AccuStem合作開展這個臨床項目。”“我對StemPrinter測試的基礎非常感興趣,並認爲它可能對乳腺癌乃至許多其他腫瘤類型的治療計劃產生重要影響。”
關於 accuStem
AccuStem 是一家臨床階段診斷公司,致力於優化所有癌症患者的預後和生活質量。我們計劃通過提供專有分子測試來推動醫療保健領域的創新,以解決從癌症篩查到治療和監測等未得到滿足的臨床需求。通過調查諸如腫瘤 “乾性” 之類的新疾病途徑,我們相信我們的工具將幫助醫療團隊更好地瞭解每位患者癌症的生物學,從而做出更明智的決策。欲瞭解更多信息,請訪問。
大學醫院簡介 /俄亥俄州克利夫蘭
大學醫院成立於 1866 年,通過由 21 家醫院(包括五家合資企業)、50 多個醫療中心和門診設施以及位於俄亥俄州北部 16 個縣的 200 多個醫生辦公室組成的綜合網絡來滿足患者的需求。該系統的旗艦第四紀醫療學術醫學中心克利夫蘭大學醫院醫學中心隸屬於凱斯西儲大學醫學院、東北俄亥俄醫科大學、牛津大學、以色列理工學院和 臺灣大學醫學院。主校區還包括UH Rainbow Babies & Children's Hospital,該醫院位居全美頂級兒童醫院之列;UH MacDonald女子醫院,這是俄亥俄州唯一一家女性醫院;以及UH Seidman癌症中心,它是NCI指定的凱斯綜合癌症中心的一部分。UH 是美國一些最負盛名的臨床和研究項目的所在地,有 3,000 多項活躍的臨床試驗和研究正在進行中。在包括《美國新聞與世界報道》中的 “美國最佳醫院” 在內的全國排名調查中,UH Cleveland醫學中心長期以來一直是表現最好的醫院之一。UH 還是 19 個臨床護理提供和研究機構的所在地。UH 是俄亥俄州東北部最大的僱主之一,擁有 30,000 多名員工。